lobbying_activities: 3440281

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3440281	97250792-ba63-41d9-aa3c-ce0fd2d17286	Q3	AARP	1694	AARP	2025	third_quarter	PHA	H.R. 1, the One Big Beautiful Bill Act of 2025. No bill number. Discussed drug supply chain and Executive Order on strategic reserve of active pharmaceutical ingredients. S. 2620, the Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act of 2025. S. 1784/H.R. 4191, the Mapping America's Pharmaceutical Supply (MAPS) Act of 2025. S.832/H.R. 1492, the Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. No bill number. Discussed the Medicare drug price negotiation program. No bill number. Discussed pharmacy benefit manager reforms. No bill number. Discussed Most Favored Nation drug pricing proposals.	Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office		3810000	0	0	2025-10-17T11:25:59-04:00